None listed
Conditions
Interventions
Intervention1: Dolutegravir dispersible tablets 10 mg: It is an single dose cross over study with two periods. The subject may receive test or reference product as per the randomization schedule in in
Sponsors
Mylan Laboratories Limited
Eligibility
Inclusion criteria
Inclusion criteria: Subjects must fulfill all of the following criteria to be considered for inclusion into this study: i. Normal healthy adult male and female (not of childbearing potential) human subjects, age between 18 to 45 years (inclusive of both). ii. Body mass index of ï?³ 18.5 kg/m2 and ï?£ 24.9 kg/m2 and weight ï?³ 50.00 kg. iii. Healthy according to the laboratory results and physical examination, performed within 21 days prior to the commencement of the dosing in Period-1. iv. Subject whose clinical laboratory values are within normal limits or clinically insignificant as determined by physician or principal investigator to be of no clinical significance. v. Have normal ECG, Chest X-ray and vital signs. vi. Non-smoker and Non-alcoholic. vii. Subject able to communicate effectively and willing to provide informed consent. viii. Subject willing to adhere to protocol requirements as evidenced by informed consent approved by an Independent Ethics Committee (IEC). ix. Subject is postmenopausal for at least 1 year Or is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the study subject).
Exclusion criteria
Exclusion criteria: A subject will not be eligible for study participation if he/she meets any of the following criteria: i. Any history of allergy or hypersensitivity to Dolutegravir or other related drugs. ii. Positive test result for hepatitis B surface antigen (HBs Ag), hepatitis C virus antibody (HCV Ab) or HIV-1 antibody or HIV Type 2 (HIV-2) antibody (HIV Ab) or VDRL / syphilis. iii. The study drug is contraindicated for medical reasons. iv. Amenorrhea or irregular menstrual periods (defined unable to predict within 7 days) during past 6 months for females. v. Any history or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, dermatological, neurological, psychiatric diseases or disorders and â??Clinically significant abnormal values of laboratory parametersâ??. vi. Any history of bleeding disorders, peptic ulcer diseases, hemorrhoids, wounds/ ulcers. vii. History or presence of drug abuse in the past one year. viii. Difficulty in swallowing tablets/capsules. ix. Any history of difficulty in donating blood. x. Had clinically significant abnormal values of laboratory parameters. xi. Blood pressure is 129/79 millimeters of mercury (Systolic blood pressure/ Diastolic blood pressure). xii. Pulse rate less than 60 beats / minute and more than 100 beats / minute. xiii. Usage of any prescribed medication during last 14 days and for OTC medicinal products, herbal products during the last 07 days preceding the first dosing. xiv. Any clinically significant illness during 3 months before screening. xv. Participation in a drug research study/donation of blood within past 90 days. xvi. Alanine transaminase (ALT) > 1.5 times upper normal limit. xvii. Bilirubin >1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin xviii. Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilberts syndrome or asymptomatic gallstones). xix. Consideration by the investigator, for any reason that the subject is an unsuitable candidate to receive study drug. Subject positive for breath alcohol test, urine screen for drugs of abuse [Cannabinoids (Marijuana / Tetra Hydro Cannabinoids-THC), Cocaine, Opiates (morphine), Amphetamine, Barbiturates and Benzodiazepines] at the time of each period check-in will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the oral bioequivalence study of Dolutegravir dispersible tablets 10 mg of Mylan Laboratories Limited, India with with GSK1349572, CQ, 5.0 mg, TAB-D (2Ã?5mg) (Dolutegravir Dispersible tablets 5mg) Glaxo Operations UK Limited (trading as Glaxo Wellcome Operations), Priory Street, Ware, Hertfordshire, SG12 0DJ in normal healthy adult male and female (not of childbearing potential) human subjects under fed conditions.Timepoint: Sampling Schedule | — |
Secondary
| Measure | Time frame |
|---|---|
| To monitor the adverse events and to ensure the safety of the subjects.Timepoint: 45 days clinical schedule | — |
Countries
India
Contacts
Public ContactDr Chakravarthy K MBBS MD
Aizant Drug Research Solutions Private Limited
Outcome results
None listed